Breaking News

Financial Report: BASi

February 10, 2016

Service revenue down 22% in the quarter

Financial Report: BASi

4Q Revenues: $5.0 million (-23%)

4Q Loss: $721,000 (loss of $404,000 4Q14)

FY Revenues: $22.7 million (-8%)

FY Earnings: $1.1 million (loss of $1.1 million FY14)

Comments: Service revenue for the quarter decreased 22% to $3.8 million, negatively impacted by fewer bioequivalence studies, as well as fewer samples received and analyzed. Product revenue was $1.1 million, down 25% impacted by lower sales of analytical instruments relating to Culex.
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research